Media & Publications
BIRMINGHAM, Ala. – TriAltus Bioscience, LLC today announced the launch of its Activated Im7 affinity chromatography resin for the CL7/Im7 protein purification system. This new version more than doubles the single-step protein purification system’s original binding capacity from 15 – 20 mg/ml to 35 – 40 mg/ml of CL7-tagged protein. Read more.
Chinese Scientists Use TriAltus Bioscience’s CL-7 Purification System to Purify CRISPR-associated Proteins
BIRMINGHAM, Ala. (August 29, 2018)—TriAltus Bioscience, LLC today announced that scientists at Hubei University in China successfully co-expressed and purified ribonucleoprotein complexes—including Cas9 and Cas12a CRISPR-associated proteins—from E. coli in a single step using the company’s licensed CL-7 purification technology. The Hubei scientists published the results of their work in late July. “This team’s success […]
TriAltus Bioscience Announces Licensing Agreement with UAB and Begins to Commercialize Novel Protein Purification Technology
New method saves time, increases yield and purity, and reduces protein preparation costs TriAltus Bioscience, LLC today announced that it has licensed a novel protein purification platform from The University of Alabama at Birmingham (UAB) and is already working to commercialize the technology. The terms of the agreement were not disclosed.
In The News
TriAltus Bioscience has been recognized by the Birmingham Business Alliance as one of its bioscience companies to watch in this growing industry sector. Read more.
What prompted the commercialization of our CL-7 protein purification system? After the PNAS paper, this article appeared in the UAB News. Learn why we thought CL-7 was so interesting. Read more.
Read about the launch of TriAltus Bioscience in our first news story, courtesy of the Birmingham Business Journal.